{"id":"lorcaserin-phentermine-hcl","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Dizziness"},{"rate":"8-12","effect":"Nausea"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Constipation"},{"rate":"5-8","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lorcaserin selectively activates serotonin 5-HT2C receptors in the hypothalamus to promote satiety and reduce food intake. Phentermine acts as a sympathomimetic agent that stimulates the release of norepinephrine, increasing metabolic rate and appetite suppression. Together, these agents work synergistically to produce greater weight loss than either agent alone.","oneSentence":"This combination uses lorcaserin (a 5-HT2C receptor agonist) to reduce appetite and phentermine (a sympathomimetic amine) to increase energy expenditure and suppress appetite for weight management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:05.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT01987427","phase":"PHASE4","title":"A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-10-30","conditions":"Chronic Weight Management","enrollment":344}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"lorcaserin + phentermine-HCl","genericName":"lorcaserin + phentermine-HCl","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses lorcaserin (a 5-HT2C receptor agonist) to reduce appetite and phentermine (a sympathomimetic amine) to increase energy expenditure and suppress appetite for weight management. Used for Chronic weight management in adults with obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}